Sarepta Therapeutics Inc.’s (SRPT) gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.
June 21, 2024 - 14:39
By Pharos Investment Advisors Comments are Off
Sarepta Therapeutics Inc.’s (SRPT) gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014
Copyright 2023©. All Rights Reserved